Inventaire - your friends and communities are your best library - Inventaire

Treatment of visceral leishmaniasis

published in: Journal of Global Infectious Diseases

date of publication: 2010-05-01

language: English

main subject: visceral leishmaniasis

Cites articles 51

Date

Title

Authors

2010-02-11

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

Shyam Sundar
2009-09-01

Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment

Shyam Sundar
2009-06-22

Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases
2008-11-17

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity

Ruchi Singh, Poonam Salotra
2008-10-23

Paromomycin.

Koert Ritmeijer
2008-10-01

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

Michel T Vaillant, Shyam Sundar, Piero Olliaro
2007-06-01

Injectable paromomycin for Visceral leishmaniasis in India

Shyam Sundar
2007-07-01

Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy

Simon M. Collin
2007-06-29

Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis
2006-03-01

Drug unresponsiveness & combination therapy for kala-azar
2006-06-20

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

Koert Ritmeijer
2006-05-26

Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.

Koert Ritmeijer
2005-11-09

Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers

Stephen Lawn, Chris Whitty
2005-12-01

A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India

Shyam Sundar
2005-11-01

A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya
2005-05-01

Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar
2004-02-12

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

Simon M. Collin
2004-01-13

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

Shyam Sundar
2003-08-28

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study
2003-02-01

Effect of tissue penetration on AmBisome efficacy
2003-07-01

Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation
2003-05-01

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

Murari Das
2002-11-01

Oral miltefosine for Indian visceral leishmaniasis

Shyam Sundar
2002-02-01

AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
2001-11-01

A policy for leishmaniasis with respect to the prevention and control of drug resistance
2001-08-25

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

Shyam Sundar
2001-01-01

Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya
2001-01-01

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study
2001-11-01

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
2001-12-01

Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi
2000-10

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Shyam Sundar
1999-12-01

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

Article - wd:Q33929849

Welcome to Inventaire

the library of your friends and communities

you are offline